Safety Study of Adoptive Transfer of Autologous IKDC-like Cells
NCT ID: NCT02661685
Last Updated: 2021-02-18
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
PHASE1
Total Enrollment
6 participants
Study Classification
INTERVENTIONAL
Study Start Date
2016-05-31
Study Completion Date
2019-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The purpose of this study is to determine the safety of adoptive transferring autologous IKDC-like cells
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Dendritic Killer Cell-based Immunotherapy for Solid Tumors
NCT02882659
Colorectal Neoplasms
Hepatocellular Carcinoma
Neoplasm Metastasis
UNKNOWN
PHASE1
Neoantigen-expanded Autologous Immune Cell Therapy
NCT05020119
Advanced Solid Tumor
UNKNOWN
PHASE1
Immune Cell Therapy for Advanced Solid Tumors
NCT07260058
Lung Cancer (Locally Advanced or Metastatic)
Liver Cancer (Locally Advanced or Metastatic)
Colorectal Cancer (Locally Advanced or Metastatic)
+2 more
NOT_YET_RECRUITING
PHASE1/PHASE2
A Trial to Evaluate the Safety and Efficacy of NK Cells in Subjects With Myelodysplastic Syndromes
NCT05371730
Relapsed / Refractory Myelodysplastic Syndromes
NOT_YET_RECRUITING
EARLY_PHASE1
NKG2D CAR-T(KD-025) in the Treatment of Advanced NKG2DL+ Solid Tumors
NCT06509490
Safety Issues
RECRUITING
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Cancer immunosurveillance in mice and human protects the host from outgrowth of tumor cells. This may establish a sufficient rationale for cancer immunotherapy that aims to control or eradicate tumor by an induction of effective anti-tumor immunity. The interest in developing cancer immunotherapy has intensified by the recent trials results showing durable responses in approximately 20% of patients who received various kinds of immunotherapy including adoptive transfer of tumor-specific T cells, cancer vaccines, and T cell response checkpoint blockade inhibition. Discoveries to date, natural killer (NK) cell function positively associates with reduction of cancer risk and with better survival of gastrointestinal stromal tumor patients. Interferon-producing killer dendritic cells (IKDCs) are a subpopulation of NK cells discovered in the mouse spleen, which can lyse tumor cells and acquire antigen presentation cell (APC) activity. We found putative IKDCs in human peripheral blood mononuclear cells (PBMCs); meanwhile, we also developed a method to expand IKDC-like cells from murine bone marrow and human PBMC ex vivo. The expanded human IKDC-like cells are cytotoxic toward several human leukemia cell lines and are capable to activate allogeneic T cells. For the in vivo anti-tumor activity, we found that two transfers of syngeneic murine IKDC-like cells reduced tumor burden in B16/OVA and B16/F10 melanoma and Lewis lung carcinoma models, and enhanced interferon (IFN)-γ production by the splenocytes of the tumor-bearing mice. Moreover, six transfers of IKDC-like cell significantly prolonged the survival of mice bearing B16/F10 melanoma. Based on these preclinical results, we hypothesize anti-tumor activity of human IKDC-like cells. We thus propose a phase 1 clinical trial to assess the safety of autologous IKDC-like cell therapy in metastatic cancer patients for determination of the maximum tolerated dose, and to monitor the immune parameters in patients before and after the IKDC-like cell transfer to investigate the therapeutic mechanism and biomarkers.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Neoplasm Metastasis
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NA
Intervention Model
SINGLE_GROUP
3+3 statistics model
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
autologous IKDC-like cell
Received autologous IKDC-like cells
Group Type
EXPERIMENTAL
autologous IKDC-like cells
Intervention Type
BIOLOGICAL
Subject received autologous IKDC-like cells every 14 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
autologous IKDC-like cells
Subject received autologous IKDC-like cells every 14 days
Intervention Type
BIOLOGICAL
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Histologically confirmed metastatic/recurrent non-hematological cancer, stage IV at study entry.
* Age: 21-75 years.
* ECOG performance status 0-1.
* Patients must have at least one measurable lesion.
* Patients' disease must have failed at least one-line of standard chemotherapy/targeted therapy or other treatment in the metastatic setting.
* Patients' estimated life expectancy is more than 3 months.
* Patients who refuse chemotherapy, or who are physiologically unsuitable for chemotherapy or any other standard therapy per investigator's discretion will be considered eligible for this trial.
* Patients must have adequate bone marrow function, defined as WBC ≥ 3500/mm3, neutrophil ≥ 1500/mm3, lymphocyte ≥ 1,000/mm3, and platelet ≥ 100,000/mm3.
* Patients must have adequate liver and renal function, defined as serum alanine transaminase (ALT) and aspartate transaminase (AST) ≤ 5 times normal, bilirubin ≤ 1.5 times normal range, and creatinine ≤ 1.5 times upper normal limit.
* All patients should have documentation of negative result of penicillin test.
* Women or men of reproductive potential may not participate unless they have agreed to use an effective contraceptive method.
* All patients must be informed of the investigational nature of this study and must sign and give written informed consent.
* Age: 21-75 years.
* ECOG performance status 0-1.
* Patients must have at least one measurable lesion.
* Patients' disease must have failed at least one-line of standard chemotherapy/targeted therapy or other treatment in the metastatic setting.
* Patients' estimated life expectancy is more than 3 months.
* Patients who refuse chemotherapy, or who are physiologically unsuitable for chemotherapy or any other standard therapy per investigator's discretion will be considered eligible for this trial.
* Patients must have adequate bone marrow function, defined as WBC ≥ 3500/mm3, neutrophil ≥ 1500/mm3, lymphocyte ≥ 1,000/mm3, and platelet ≥ 100,000/mm3.
* Patients must have adequate liver and renal function, defined as serum alanine transaminase (ALT) and aspartate transaminase (AST) ≤ 5 times normal, bilirubin ≤ 1.5 times normal range, and creatinine ≤ 1.5 times upper normal limit.
* All patients should have documentation of negative result of penicillin test.
* Women or men of reproductive potential may not participate unless they have agreed to use an effective contraceptive method.
* All patients must be informed of the investigational nature of this study and must sign and give written informed consent.
Exclusion Criteria
* Subjects with metastatic cancer in disease progression (expected survival time \< 3 months).
* Subjects who have had chemotherapy less than 4 weeks before the start of trial.
* Subjects who received IFN-γ or GM-CSF less than 4 weeks before the start of trial.
* Subjects who are HIV, HBV, or HCV positive.
* Patients who have central nervous system metastasis except for those whose CNS disease have been treated with radiotherapy (Disease-free \> 6 months) and/or surgery and have been stable for at least two weeks.
* Patients who have active acute or chronic infection (at the discretion of the investigator).
* Pregnant or breast-nursing women.
* Patients who have active cardiac disease requiring therapy for failure, angina, arrhythmia, or infarction within the preceding 6 months (exception: any patient whose cardiac failure is compensated on medications).
* Subjects who have received corticosteroids or other immunosuppressive agents less than 4 weeks before starting trial.
* Subjects who have asthma and/or are on treatment for asthma.
* Subjects with history of autoimmune disease, such as lupus, multiple sclerosis, Ankylosing Spondylitis, Systemic Sclerosis.
* Subjects with a history of other systemic disease..
* History of neoplastic disease within the last 5 years except for carcinoma in situ of the cervix, superficial bladder cancer or basal/squamous cell carcinoma of the skin.
* Subjects who present with open wounds.
* Subjects who have had chemotherapy less than 4 weeks before the start of trial.
* Subjects who received IFN-γ or GM-CSF less than 4 weeks before the start of trial.
* Subjects who are HIV, HBV, or HCV positive.
* Patients who have central nervous system metastasis except for those whose CNS disease have been treated with radiotherapy (Disease-free \> 6 months) and/or surgery and have been stable for at least two weeks.
* Patients who have active acute or chronic infection (at the discretion of the investigator).
* Pregnant or breast-nursing women.
* Patients who have active cardiac disease requiring therapy for failure, angina, arrhythmia, or infarction within the preceding 6 months (exception: any patient whose cardiac failure is compensated on medications).
* Subjects who have received corticosteroids or other immunosuppressive agents less than 4 weeks before starting trial.
* Subjects who have asthma and/or are on treatment for asthma.
* Subjects with history of autoimmune disease, such as lupus, multiple sclerosis, Ankylosing Spondylitis, Systemic Sclerosis.
* Subjects with a history of other systemic disease..
* History of neoplastic disease within the last 5 years except for carcinoma in situ of the cervix, superficial bladder cancer or basal/squamous cell carcinoma of the skin.
* Subjects who present with open wounds.
Minimum Eligible Age
21 Years
Maximum Eligible Age
75 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ministry of Science and Technology, Taiwan
OTHER_GOV
Sponsor Role
collaborator
Academia Sinica, Taiwan
OTHER
Sponsor Role
collaborator
National Defense Medical Center, Taiwan
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ming-Shen Dai
Attending physician
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ming-Shen Dai, MD/PhD
Role: PRINCIPAL_INVESTIGATOR
Attending Physician
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tri-Service General Hospital
Taipei, , Taiwan
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Taiwan
References
Explore related publications, articles, or registry entries linked to this study.
Smyth MJ, Thia KY, Street SE, Cretney E, Trapani JA, Taniguchi M, Kawano T, Pelikan SB, Crowe NY, Godfrey DI. Differential tumor surveillance by natural killer (NK) and NKT cells. J Exp Med. 2000 Feb 21;191(4):661-8. doi: 10.1084/jem.191.4.661.
Reference Type
BACKGROUND
Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ. Natural innate and adaptive immunity to cancer. Annu Rev Immunol. 2011;29:235-71. doi: 10.1146/annurev-immunol-031210-101324.
Reference Type
BACKGROUND
Galon J, Angell HK, Bedognetti D, Marincola FM. The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. Immunity. 2013 Jul 25;39(1):11-26. doi: 10.1016/j.immuni.2013.07.008.
Reference Type
BACKGROUND
Fridman WH, Pages F, Sautes-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. 2012 Mar 15;12(4):298-306. doi: 10.1038/nrc3245.
Reference Type
BACKGROUND
Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013 Jul 25;39(1):1-10. doi: 10.1016/j.immuni.2013.07.012.
Reference Type
BACKGROUND
Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, Citrin DE, Restifo NP, Robbins PF, Wunderlich JR, Morton KE, Laurencot CM, Steinberg SM, White DE, Dudley ME. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res. 2011 Jul 1;17(13):4550-7. doi: 10.1158/1078-0432.CCR-11-0116. Epub 2011 Apr 15.
Reference Type
BACKGROUND
Kochenderfer JN, Rosenberg SA. Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors. Nat Rev Clin Oncol. 2013 May;10(5):267-76. doi: 10.1038/nrclinonc.2013.46. Epub 2013 Apr 2.
Reference Type
BACKGROUND
Galluzzi L, Vacchelli E, Eggermont A, Fridman WH, Galon J, Sautes-Fridman C, Tartour E, Zitvogel L, Kroemer G. Trial Watch: Adoptive cell transfer immunotherapy. Oncoimmunology. 2012 May 1;1(3):306-315. doi: 10.4161/onci.19549.
Reference Type
BACKGROUND
Thanendrarajan S, Nowak M, Abken H, Schmidt-Wolf IG. Combining cytokine-induced killer cells with vaccination in cancer immunotherapy: more than one plus one? Leuk Res. 2011 Sep;35(9):1136-42. doi: 10.1016/j.leukres.2011.05.005. Epub 2011 Jun 8.
Reference Type
BACKGROUND
Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer. 2008 Apr;8(4):299-308. doi: 10.1038/nrc2355.
Reference Type
BACKGROUND
Imai K, Matsuyama S, Miyake S, Suga K, Nakachi K. Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. Lancet. 2000 Nov 25;356(9244):1795-9. doi: 10.1016/S0140-6736(00)03231-1.
Reference Type
BACKGROUND
Menard C, Blay JY, Borg C, Michiels S, Ghiringhelli F, Robert C, Nonn C, Chaput N, Taieb J, Delahaye NF, Flament C, Emile JF, Le Cesne A, Zitvogel L. Natural killer cell IFN-gamma levels predict long-term survival with imatinib mesylate therapy in gastrointestinal stromal tumor-bearing patients. Cancer Res. 2009 Apr 15;69(8):3563-9. doi: 10.1158/0008-5472.CAN-08-3807. Epub 2009 Apr 7.
Reference Type
BACKGROUND
Rusakiewicz S, Semeraro M, Sarabi M, Desbois M, Locher C, Mendez R, Vimond N, Concha A, Garrido F, Isambert N, Chaigneau L, Le Brun-Ly V, Dubreuil P, Cremer I, Caignard A, Poirier-Colame V, Chaba K, Flament C, Halama N, Jager D, Eggermont A, Bonvalot S, Commo F, Terrier P, Opolon P, Emile JF, Coindre JM, Kroemer G, Chaput N, Le Cesne A, Blay JY, Zitvogel L. Immune infiltrates are prognostic factors in localized gastrointestinal stromal tumors. Cancer Res. 2013 Jun 15;73(12):3499-510. doi: 10.1158/0008-5472.CAN-13-0371. Epub 2013 Apr 16.
Reference Type
BACKGROUND
Duan X, Deng L, Chen X, Lu Y, Zhang Q, Zhang K, Hu Y, Zeng J, Sun W. Clinical significance of the immunostimulatory MHC class I chain-related molecule A and NKG2D receptor on NK cells in pancreatic cancer. Med Oncol. 2011 Jun;28(2):466-74. doi: 10.1007/s12032-010-9480-9. Epub 2010 Mar 31.
Reference Type
BACKGROUND
McGilvray RW, Eagle RA, Watson NF, Al-Attar A, Ball G, Jafferji I, Trowsdale J, Durrant LG. NKG2D ligand expression in human colorectal cancer reveals associations with prognosis and evidence for immunoediting. Clin Cancer Res. 2009 Nov 15;15(22):6993-7002. doi: 10.1158/1078-0432.CCR-09-0991. Epub 2009 Oct 27.
Reference Type
BACKGROUND
de Kruijf EM, Sajet A, van Nes JG, Putter H, Smit VT, Eagle RA, Jafferji I, Trowsdale J, Liefers GJ, van de Velde CJ, Kuppen PJ. NKG2D ligand tumor expression and association with clinical outcome in early breast cancer patients: an observational study. BMC Cancer. 2012 Jan 18;12:24. doi: 10.1186/1471-2407-12-24.
Reference Type
BACKGROUND
Mamessier E, Sylvain A, Thibult ML, Houvenaeghel G, Jacquemier J, Castellano R, Goncalves A, Andre P, Romagne F, Thibault G, Viens P, Birnbaum D, Bertucci F, Moretta A, Olive D. Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity. J Clin Invest. 2011 Sep;121(9):3609-22. doi: 10.1172/JCI45816. Epub 2011 Aug 15.
Reference Type
BACKGROUND
Taieb J, Chaput N, Menard C, Apetoh L, Ullrich E, Bonmort M, Pequignot M, Casares N, Terme M, Flament C, Opolon P, Lecluse Y, Metivier D, Tomasello E, Vivier E, Ghiringhelli F, Martin F, Klatzmann D, Poynard T, Tursz T, Raposo G, Yagita H, Ryffel B, Kroemer G, Zitvogel L. A novel dendritic cell subset involved in tumor immunosurveillance. Nat Med. 2006 Feb;12(2):214-9. doi: 10.1038/nm1356. Epub 2006 Jan 29.
Reference Type
BACKGROUND
Chan CW, Crafton E, Fan HN, Flook J, Yoshimura K, Skarica M, Brockstedt D, Dubensky TW, Stins MF, Lanier LL, Pardoll DM, Housseau F. Interferon-producing killer dendritic cells provide a link between innate and adaptive immunity. Nat Med. 2006 Feb;12(2):207-13. doi: 10.1038/nm1352. Epub 2006 Jan 29.
Reference Type
BACKGROUND
Himoudi N, Yan M, Bouma G, Morgenstern D, Wallace R, Seddon B, Buddle J, Eddaoudi A, Howe SJ, Cooper N, Anderson J. Migratory and antigen presentation functions of IFN-producing killer dendritic cells. Cancer Res. 2009 Aug 15;69(16):6598-606. doi: 10.1158/0008-5472.CAN-09-0501. Epub 2009 Aug 4.
Reference Type
BACKGROUND
Pletneva M, Fan H, Park JJ, Radojcic V, Jie C, Yu Y, Chan C, Redwood A, Pardoll D, Housseau F. IFN-producing killer dendritic cells are antigen-presenting cells endowed with T-cell cross-priming capacity. Cancer Res. 2009 Aug 15;69(16):6607-14. doi: 10.1158/0008-5472.CAN-09-0508.
Reference Type
BACKGROUND
Terme M, Mignot G, Ullrich E, Bonmort M, Minard-Colin V, Jacquet A, Schultze JL, Kroemer G, Leclerc C, Chaput N, Zitvogel L. The dendritic cell-like functions of IFN-producing killer dendritic cells reside in the CD11b+ subset and are licensed by tumor cells. Cancer Res. 2009 Aug 15;69(16):6590-7. doi: 10.1158/0008-5472.CAN-08-4473.
Reference Type
BACKGROUND
Chaudhry UI, Plitas G, Burt BM, Kingham TP, Raab JR, DeMatteo RP. NK dendritic cells expanded in IL-15 exhibit antitumor responses in vivo. J Immunol. 2007 Oct 1;179(7):4654-60. doi: 10.4049/jimmunol.179.7.4654.
Reference Type
BACKGROUND
Himoudi N, Nabarro S, Buddle J, Eddaoudi A, Thrasher AJ, Anderson J. Bone marrow-derived IFN-producing killer dendritic cells account for the tumoricidal activity of unpulsed dendritic cells. J Immunol. 2008 Nov 1;181(9):6654-63. doi: 10.4049/jimmunol.181.9.6654.
Reference Type
BACKGROUND
Liao N, Lee G, Chang C: Generation of murine and human interferon-producing killer cell-like cells with anti-tumor activity. . (patent pending) 2013.
Reference Type
BACKGROUND
Lanier LL, Phillips JH, Hackett J Jr, Tutt M, Kumar V. Natural killer cells: definition of a cell type rather than a function. J Immunol. 1986 Nov 1;137(9):2735-9. No abstract available.
Reference Type
BACKGROUND
Burt BM, Plitas G, Nguyen HM, Stableford JA, Bamboat ZM, Dematteo RP. Circulating HLA-DR(+) natural killer cells have potent lytic ability and weak antigen-presenting cell function. Hum Immunol. 2008 Aug;69(8):469-74. doi: 10.1016/j.humimm.2008.06.009. Epub 2008 Jul 18.
Reference Type
BACKGROUND
Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB J. 2008 Mar;22(3):659-61. doi: 10.1096/fj.07-9574LSF. Epub 2007 Oct 17.
Reference Type
BACKGROUND
Krause SW, Gastpar R, Andreesen R, Gross C, Ullrich H, Thonigs G, Pfister K, Multhoff G. Treatment of colon and lung cancer patients with ex vivo heat shock protein 70-peptide-activated, autologous natural killer cells: a clinical phase i trial. Clin Cancer Res. 2004 Jun 1;10(11):3699-707. doi: 10.1158/1078-0432.CCR-03-0683.
Reference Type
BACKGROUND
Ishikawa E, Tsuboi K, Saijo K, Harada H, Takano S, Nose T, Ohno T. Autologous natural killer cell therapy for human recurrent malignant glioma. Anticancer Res. 2004 May-Jun;24(3b):1861-71.
Reference Type
BACKGROUND
Parkhurst MR, Riley JP, Dudley ME, Rosenberg SA. Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression. Clin Cancer Res. 2011 Oct 1;17(19):6287-97. doi: 10.1158/1078-0432.CCR-11-1347. Epub 2011 Aug 15.
Reference Type
BACKGROUND
Yang YJ, Park JC, Kim HK, Kang JH, Park SY. A trial of autologous ex vivo-expanded NK cell-enriched lymphocytes with docetaxel in patients with advanced non-small cell lung cancer as second- or third-line treatment: phase IIa study. Anticancer Res. 2013 May;33(5):2115-22.
Reference Type
BACKGROUND
Yamaguchi T, Bamba K, Kitayama A, Kuroiwa Y, Yoshimatsu K, Shimakawa T, Ogawa K, Sekine T, Shimizu N, Yamamoto K. Long-term intravenous administration of activated autologous lymphocytes for cancer patients does not induce antinuclear antibody and rheumatoid factor. Anticancer Res. 2004 Jul-Aug;24(4):2423-9.
Reference Type
BACKGROUND
Delyon J, Mateus C, Lefeuvre D, Lanoy E, Zitvogel L, Chaput N, Roy S, Eggermont AM, Routier E, Robert C. Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival. Ann Oncol. 2013 Jun;24(6):1697-703. doi: 10.1093/annonc/mdt027. Epub 2013 Feb 24.
Reference Type
BACKGROUND
Ku GY, Yuan J, Page DB, Schroeder SE, Panageas KS, Carvajal RD, Chapman PB, Schwartz GK, Allison JP, Wolchok JD. Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival. Cancer. 2010 Apr 1;116(7):1767-75. doi: 10.1002/cncr.24951.
Reference Type
BACKGROUND
Carthon BC, Wolchok JD, Yuan J, Kamat A, Ng Tang DS, Sun J, Ku G, Troncoso P, Logothetis CJ, Allison JP, Sharma P. Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin Cancer Res. 2010 May 15;16(10):2861-71. doi: 10.1158/1078-0432.CCR-10-0569. Epub 2010 May 11.
Reference Type
BACKGROUND
Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon RA, Reed K, Burke MM, Caldwell A, Kronenberg SA, Agunwamba BU, Zhang X, Lowy I, Inzunza HD, Feely W, Horak CE, Hong Q, Korman AJ, Wigginton JM, Gupta A, Sznol M. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013 Jul 11;369(2):122-33. doi: 10.1056/NEJMoa1302369. Epub 2013 Jun 2.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IKDC-001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer
NCT06253520
RECRUITING
PHASE1
NK Cells Infusion for Advanced Malignancies
NCT03619954
UNKNOWN
PHASE1
Gene Expression Profiling of Malignant Tumor Predict the Therapeutic Response of DC-CIK Immunotherapy
NCT01906632
COMPLETED
NA
Safety and Efficacy of Allogeneic NK Cells Therapy in Patients With Advanced Hepatocellular Carcinoma
NCT04162158
UNKNOWN
PHASE1/PHASE2
DC Vaccine Combined With CIK Cells in Patients With SCLC
NCT02688673
UNKNOWN
PHASE1/PHASE2
Donor Natural Killer Cells After Donor Stem Cell Transplant in Treating Patients With Advanced Cancer
NCT00823524
COMPLETED
PHASE1/PHASE2
DC/NK Cell Therapy
NCT07202611
RECRUITING
PHASE2
Clinical Study of DC-CIK Cells as a Post-remission Treatment for Malignant Tumors
NCT04292769
UNKNOWN
PHASE3
Anti-PD-1 Alone or Combined With Autologous Cell Therapy in Advanced NSCLC
NCT03360630
COMPLETED
PHASE1/PHASE2
NKG2D-CAR-NK92 Cells Immunotherapy for Solid Tumors
NCT05528341
RECRUITING
PHASE1
Autologous Dendritic Cells in Treating Patients With Metastatic Kidney Cancer
NCT01826877
COMPLETED
PHASE1
Exploratory Clinical Study on Memory NK Cell Therapy for Advanced Metastatic Solid Tumors
NCT07274449
ACTIVE_NOT_RECRUITING
PHASE1/PHASE2
Cytokine Induced Killer Cells Stimulated by DC Immunotherapy for Renal Cell Carcinoma
NCT01240005
UNKNOWN
PHASE1/PHASE2
NKG2D CAR-T(KD-025) in the Treatment of Relapsed or Refractory NKG2DL+ Tumors
NCT04550663
UNKNOWN
PHASE1
Dendritic Cells (DC) Vaccine for Metastatic Melanoma
NCT01042366
TERMINATED
PHASE2
DCs Vaccine Combined With Cytokine-induced Killer Cells in Patients With AML
NCT01898663
RECRUITING
PHASE1/PHASE2
Study of Gene Expression Profiling and Immunological Mechanism Affects the Response of Immunotherapy
NCT01884168
COMPLETED
Neoantigen Derived DCs as Cancer Treatment
NCT05767684
RECRUITING
PHASE1
DC Vaccine Combined With CIK Cells in Patients With Renal Cell Carcinoma
NCT01924156
UNKNOWN
PHASE1/PHASE2
Vaccination With Dendritic Cells Loaded With Brain Tumor Stem Cells for Progressive Malignant Brain Tumor
NCT01171469
COMPLETED
PHASE1
Universal Dual-target NKG2D-NKp44 CAR-T Cells in Advanced Solid Tumors
NCT05976906
UNKNOWN
PHASE1
Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor
NCT06105021
ACTIVE_NOT_RECRUITING
PHASE1/PHASE2
Autologous Natural Killer T Cells Infusion for the Treatment of Cancer
NCT01801852
UNKNOWN
NA
Safety Study of Cord Blood-derived Cytokine-induced Killer Cells in Patients With Solid Tumor After Radical Resection
NCT01914263
UNKNOWN
PHASE1
Autologous Antigen-activated Dendritic Cells in the Treatment of Patients With Breast Cancer
NCT03113019
UNKNOWN
EARLY_PHASE1